Markets:

Overview

News

Currencies

International

Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

46.45 +1.23 (+2.72%)

Streaming Delayed Price Updated: 9:52 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future ↗

November 11, 2025

Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.

Via Benzinga

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet ↗

August 15, 2025

Via Stocktwits

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Soleno Therapeutics's Earnings: A Preview ↗

August 05, 2025

Via Benzinga

PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗

November 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

These stocks are moving in today's session ↗

November 05, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

November 05, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

November 05, 2025

Via Benzinga

What's going on in today's after hours session ↗

November 04, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗

September 24, 2025

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Via Benzinga

Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges ↗

September 24, 2025

The companies are working on treatments for a rare, genetic disease that can cause excessive hunger.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside ↗

September 10, 2025

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.

Via Stocktwits

Topics Death

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe ↗

August 15, 2025

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.

Via Benzinga

Soleno (SLNO) Q2 Revenue Jumps 30% ↗

August 06, 2025

Via The Motley Fool

Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance ↗

August 06, 2025

Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch.

Via Chartmill

Topics Earnings

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress ↗

June 30, 2025

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.